Literature DB >> 21310234

Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.

Veronica Francardo1, Alessandra Recchia, Nataljia Popovic, Daniel Andersson, Hans Nissbrandt, M Angela Cenci.   

Abstract

6-Hydroxydopamine (6-OHDA) lesions are being used in the mouse for basic research on Parkinson's disease and L-DOPA-induced dyskinesia. We set out to compare unilateral lesion models produced by intrastriatal or intramesencephalic injections of a fixed 6-OHDA concentration (3.2 μg/μl) in C57BL/6 mice. In the first experiment, toxin injections were performed either at two striatal coordinates (1 or 2 μl per site, termed "striatum(2 × 1 μl)" and "striatum(2 × 2 μl)" models), in the medial forebrain bundle (MFB), or in the substantia nigra pars compacta (SN) (1 μl per site). All the four lesion models produced significant forelimb use asymmetry, but spontaneous turning asymmetry only occurred in the MFB and striatum(2 × 2 μl) models. After the behavioral studies, the induction of phosphorylated extracellular signal-regulated kinases 1 and 2 (pERK1/2) by acute L-DOPA (30 mg/kg) was used as a marker of post-synaptic supersensitivity. Striatal pERK1/2 expression was sparse in the SN and striatum(2 × 1 μl) groups, but pronounced in the striatum(2 × 2 μl) and MFB-lesioned mice. In further experiments, mice with MFB and striatal(2 × 2 μl) lesions were used to compare behavioral and molecular responses to chronic L-DOPA treatment (12 days at 3 and 6 mg/kg/day). Maximally severe abnormal involuntary movements (AIMs) occurred in all MFB-lesioned mice, whereas only 35% of the mice with striatal lesions developed dyskinesia. Striatal tissue levels of dopamine were significantly lower in the dyskinetic animals (both MFB and striatum(2 × 2 μl) groups) in comparison with the non-dyskinetic ones. Noradrenaline levels were significantly reduced only in MFB lesioned animals and did not differ among the dyskinetic and non-dyskinetic cases with striatal lesions. In all groups, the L-DOPA-induced AIM scores correlated closely with the number of cells immunoreactive for tyrosine hydroxylase or FosB/∆FosB in the striatum. In conclusion, among the four lesion procedures examined here, only the MFB and striatum(2 × 2 μl) models yielded a degree of dopamine denervation sufficient to produce spontaneous postural asymmetry and molecular supersensitivity to L-DOPA. Both lesion models are suitable to reproduce L-DOPA-induced dyskinesia, although only MFB lesions yield a pronounced and widespread expression of post-synaptic supersensitivity markers in the striatum.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21310234     DOI: 10.1016/j.nbd.2011.01.024

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  48 in total

1.  Development of a unilaterally-lesioned 6-OHDA mouse model of Parkinson's disease.

Authors:  Sherri L Thiele; Ruth Warre; Joanne E Nash
Journal:  J Vis Exp       Date:  2012-02-14       Impact factor: 1.355

2.  Aberrant Striatal Activity in Parkinsonism and Levodopa-Induced Dyskinesia.

Authors:  Michael B Ryan; Chloe Bair-Marshall; Alexandra B Nelson
Journal:  Cell Rep       Date:  2018-06-19       Impact factor: 9.423

3.  Abnormal Cortico-Basal Ganglia Neurotransmission in a Mouse Model of l-DOPA-Induced Dyskinesia.

Authors:  Indriani Dwi Wahyu; Satomi Chiken; Taku Hasegawa; Hiromi Sano; Atsushi Nambu
Journal:  J Neurosci       Date:  2021-02-09       Impact factor: 6.167

4.  Structurally distinct α-synuclein fibrils induce robust parkinsonian pathology.

Authors:  Hideki Hayakawa; Rie Nakatani; Kensuke Ikenaka; Cesar Aguirre; Chi-Jing Choong; Hiroshi Tsuda; Seiichi Nagano; Masato Koike; Takeshi Ikeuchi; Masato Hasegawa; Stella M Papa; Yoshitaka Nagai; Hideki Mochizuki; Kousuke Baba
Journal:  Mov Disord       Date:  2019-10-23       Impact factor: 10.338

Review 5.  Critical involvement of the motor cortex in the pathophysiology and treatment of Parkinson's disease.

Authors:  David Lindenbach; Christopher Bishop
Journal:  Neurosci Biobehav Rev       Date:  2013-10-07       Impact factor: 8.989

6.  Involvement of Striatal Cholinergic Interneurons and M1 and M4 Muscarinic Receptors in Motor Symptoms of Parkinson's Disease.

Authors:  Samira Ztaou; Nicolas Maurice; Jeremy Camon; Gaëlle Guiraudie-Capraz; Lydia Kerkerian-Le Goff; Corinne Beurrier; Martine Liberge; Marianne Amalric
Journal:  J Neurosci       Date:  2016-08-31       Impact factor: 6.167

7.  The Kinase Fyn As a Novel Intermediate in L-DOPA-Induced Dyskinesia in Parkinson's Disease.

Authors:  Sara Sanz-Blasco; Melina P Bordone; Ana Damianich; Gimena Gomez; M Alejandra Bernardi; Luciana Isaja; Irene R Taravini; Diane P Hanger; M Elena Avale; Oscar S Gershanik; Juan E Ferrario
Journal:  Mol Neurobiol       Date:  2017-08-24       Impact factor: 5.590

8.  Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist.

Authors:  Hanna Iderberg; Natallia Maslava; Analisa D Thompson; Michael Bubser; Colleen M Niswender; Corey R Hopkins; Craig W Lindsley; P Jeffrey Conn; Carrie K Jones; M Angela Cenci
Journal:  Neuropharmacology       Date:  2015-03-04       Impact factor: 5.250

9.  Serotonin hyperinnervation and upregulated 5-HT2A receptor expression and motor-stimulating function in nigrostriatal dopamine-deficient Pitx3 mutant mice.

Authors:  Li Li; Guozhen Qiu; Shengyuan Ding; Fu-Ming Zhou
Journal:  Brain Res       Date:  2012-11-15       Impact factor: 3.252

10.  M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia.

Authors:  Weixing Shen; Joshua L Plotkin; Veronica Francardo; Wai Kin D Ko; Zhong Xie; Qin Li; Tim Fieblinger; Jürgen Wess; Richard R Neubig; Craig W Lindsley; P Jeffrey Conn; Paul Greengard; Erwan Bezard; M Angela Cenci; D James Surmeier
Journal:  Neuron       Date:  2015-11-18       Impact factor: 17.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.